Features

How have procurement and supply-chain executives from bio/pharma companies and their suppliers responded to recent unprecedented sourcing challenges and the resulting need to re-evaluate sourcing and supply-chain management functions? The latest study from DCAT Research & Benchmarking highlights the changes in sourcing and supply-chain strategies and organizations.

A roundup of news announcements from DCAT Member Companies in 2023 to date across the bio/pharmaceutical manufacturing value chain: from active pharmaceutical ingredients (small molecules and biologics) to drug products (solid dosage, injectables and specialty dosage forms). Which companies are making the news?

Senior executives from DCAT Member Companies highlighted their companies’ major news at the DCAT Member Company Announcement Forum at DCAT Week with the latest in expansion plans across the bio/pharmaceutical manufacturing value chain: from drug substances (small-molecules and biologics) to drug products (solid dosage and injectable product forms). Which companies are making the news?

A roundup of some key highlights from the education programs at DCAT Week: market insights on the performance of the global bio/pharmaceutical industry, perspectives on approaches in supply management, including supplier risk assessment and mitigation, an energy and chemicals outlook, and a CPO view of sustainability and how it factors into supplier selection and evaluation. 

Although a niche market, cell and gene therapy development and manufacturing continues to be an active area of investment by CDMOs/CMOs. Facing limited industry capacity, both pure-play CDMOs and bio/pharma companies with CDMO services continue to expand. A roundup of the latest expansions.

What is the potential of artificial intelligence (AI) in pharmaceutical manufacturing and what regulatory considerations come into play, including between CDMOs/CMOs and sponsor companies? The FDA has issued a discussion paper to highlight key issues and is seeking input from the industry.

With 2023 well underway, the crucial question is: how will the bio/pharmaceutical industry perform in 2023 and the near term? The DCAT Week program, Pharma Industry Outlook, will provide key market data and trends. Plus, a pharma financial outlook and analysis of M&A, partnering deals, and private and public financing into Emerging Pharma. 

A recent analysis by the management consultancy firm, Deloitte, shows that the bio/pharma industry’s return on investment (ROI) in R&D has fallen in the post-pandemic market. Projected ROI in pharma R&D in 2022 fell to 1.2%, the lowest ROI observed in the 13 years since the firm has conducted the study.

Executives at DCAT Week’s education programs will address the industry’s most pressing challenges: inflationary pressures, supply-chain disruptions in a post-pandemic environment, and geopolitical and economic uncertainty. Hear from leading experts who will provide practical insights to address these challenges, including new tools/approaches to identify and mitigate supply risk.

The US Centers for Medicare & Medicaid Services reported last month it is working on its plan for how exactly it will implement negotiations with drug manufacturers for drugs under Medicare, the US government program for individuals 65 or older. It plans to release a list of the first 10 drugs it will target for drug pricing negotiation by September.